140 related articles for article (PubMed ID: 38334173)
41. Severe hypercholesterolemia and liver disease in a 3-year old.
Patel AM; Brautbar A; Desai NK; Wilson DP
J Clin Lipidol; 2016; 10(3):650-3. PubMed ID: 27206954
[TBL] [Abstract][Full Text] [Related]
42. Rapid normalization of severe hypercholesterolemia mediated by lipoprotein X after liver transplantation in a patient with cholestasis - a case report.
Jankowski K; Wyzgał A; Wierzbicka A; Tronina O; Durlik M; Pruszczyk P
Acta Biochim Pol; 2015; 62(3):621-3. PubMed ID: 26317127
[TBL] [Abstract][Full Text] [Related]
43. Lipoprotein apheresis in the management of severe hypercholesterolemia and hyperlipoproteinemia(a)-The Portuguese experience.
Ferreira L; Palma I; Bacelar C; Queirós JA; Madureira A; Oliveira JC; Ramos MH; Cardoso H
Transfus Apher Sci; 2018 Oct; 57(5):676-680. PubMed ID: 30287070
[TBL] [Abstract][Full Text] [Related]
44. In vivo and in vitro relationship between lipoprotein-X and bile salts in cholestasis.
Frisón JC; Ras MR; Rubiés-Prat J; Salvá JA; Masdeu S; Bacardí R
Digestion; 1979; 19(6):411-4. PubMed ID: 535670
[TBL] [Abstract][Full Text] [Related]
45. Formation of lipoprotein-X. Its relationship to bile compounds.
Manzato E; Fellin R; Baggio G; Walch S; Neubeck W; Seidel D
J Clin Invest; 1976 May; 57(5):1248-60. PubMed ID: 816809
[TBL] [Abstract][Full Text] [Related]
46. Evolocumab and lipoprotein apheresis combination therapy may have synergic effects to reduce low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemia: A case report.
Zenti MG; Stefanutti C; Sanga V; Altomari A; Fabris A; Dauriz M; Bonora E
J Clin Apher; 2018 Aug; 33(4):546-550. PubMed ID: 29638018
[TBL] [Abstract][Full Text] [Related]
47. Divide et Vinces, Therapeutic Apheresis in Nephrological Clinical Practice.
Mantilla J; Peña D; Molano-Triviño A; Zúñiga E; Castellanos-De La Hoz JC
Blood Purif; 2024; 53(3):162-169. PubMed ID: 38113864
[TBL] [Abstract][Full Text] [Related]
48. Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease.
Heigl F; Hettich R; Lotz N; Reeg H; Pflederer T; Osterkorn D; Osterkorn K; Klingel R
Clin Res Cardiol Suppl; 2015 Apr; 10(Suppl 1):8-13. PubMed ID: 25672934
[TBL] [Abstract][Full Text] [Related]
49. Lipoprotein(a) and other lipoproteins in hypothyroid patients before and after thyroid replacement therapy.
Becerra A; Bellido D; Luengo A; Piédrola G; De Luis DA
Clin Nutr; 1999 Oct; 18(5):319-22. PubMed ID: 10601541
[TBL] [Abstract][Full Text] [Related]
50. [Serum lipoprotein (a) levels during treatment with LDL apheresis for homozygous familial hypercholesterolemia].
Lasunción MA; Teruel JL; Alvarez JJ; Gómez-Coronado D; Ortuño J; Herrera E
Med Clin (Barc); 1992 Oct; 99(14):541-4. PubMed ID: 1434990
[TBL] [Abstract][Full Text] [Related]
51. Vanishing bile duct syndrome in Hodgkin's lymphoma: A case report and literature review.
Bakhit M; McCarty TR; Park S; Njei B; Cho M; Karagozian R; Liapakis A
World J Gastroenterol; 2017 Jan; 23(2):366-372. PubMed ID: 28127210
[TBL] [Abstract][Full Text] [Related]
52. Hyperviscosity syndrome in a hypercholesterolemic patient with primary biliary cirrhosis.
Rosenson RS; Baker AL; Chow MJ; Hay RV
Gastroenterology; 1990 May; 98(5 Pt 1):1351-7. PubMed ID: 2323525
[TBL] [Abstract][Full Text] [Related]
53. Quantitative determination of the abnormal lipoprotein of cholestasis, LP-X, in liver disease.
Ritland S
Scand J Gastroenterol; 1975; 10(1):5-15. PubMed ID: 164686
[TBL] [Abstract][Full Text] [Related]
54. Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis centre.
Mickiewicz A; Borowiec-Wolna J; Bachorski W; Gilis-Malinowska N; Gałąska R; Raczak G; Chmara M; Wasąg B; Jaguszewski MJ; Fijałkowski M; Gruchała M
Cardiol J; 2019; 26(6):669-679. PubMed ID: 30234904
[TBL] [Abstract][Full Text] [Related]
55. On the metabolism of lipoprotein-X (LP-X).
Seidel D; Büff HU; Fauser U; Bleyl U
Clin Chim Acta; 1976 Jan; 66(2):195-207. PubMed ID: 173481
[TBL] [Abstract][Full Text] [Related]
56. Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia.
Richter WO; Donner MG; Höfling B; Schwandt P
Metabolism; 1998 Jul; 47(7):863-8. PubMed ID: 9667236
[TBL] [Abstract][Full Text] [Related]
57. LCAT protects against Lipoprotein-X formation in a murine model of drug-induced intrahepatic cholestasis.
Amar MJA; Freeman LA; Nishida T; Sampson ML; Pryor M; Vaisman BL; Neufeld EB; Karathanasis SK; Remaley AT
Pharmacol Res Perspect; 2020 Feb; 8(1):e00554. PubMed ID: 31893124
[TBL] [Abstract][Full Text] [Related]
58. [Abnormal lipoprotein (LP-X) in the first months of life with particular reference to obstructive jaundice (author's transl)].
Lachmann D
Wien Klin Wochenschr Suppl; 1977; 69():3-28. PubMed ID: 266315
[TBL] [Abstract][Full Text] [Related]
59. Pregnancy in a patient with homozygous familial hypercholesterolemia treated with long-term low-density lipoprotein apheresis.
Kroon AA; Swinkels DW; van Dongen PW; Stalenhoef AF
Metabolism; 1994 Sep; 43(9):1164-70. PubMed ID: 8084291
[TBL] [Abstract][Full Text] [Related]
60. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis.
Attman PO; Samuelsson OG; Moberly J; Johansson AC; Ljungman S; Weiss LG; Knight-Gibson C; Alaupovic P
Kidney Int; 1999 Apr; 55(4):1536-42. PubMed ID: 10201020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
